Skip to content
Screener

Eikon Therapeutics, Inc. EIKN Total Liabilities & Equity

Total Liabilities & Equity at other companies

Gilead Sciences logo
Gilead SciencesGILD
$49.36B-11.4%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$1.03B-6.4%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$183.97M-24.2%
OnKure Therapeutics, Inc. logo
OnKure Therapeutics, Inc.OKUR
$198.69M+98.9%
Immunome logo
ImmunomeIMNM
$619.79M+80.9%
Erasca, Inc. logo
Erasca, Inc.ERAS
$461.23M-2.1%

Other financials

Income statement

See full
Operating income-$87.3M-22.3%
Net income-$83.0M-21.6%
EPS (diluted)-$2.46+90.9%

Balance sheet

See full
Cash & equivalents$161.2M-21.2%
Total debt$254.8M
Total equity$550.7M+186%
Total assets$850.8M

Cash flow

See full
Operating cash flow-$89.8M-64.7%
CapEx$262.0K-98.8%
Free cash flow-$90.1M-17.1%

Valuation

See full
Market cap$498.62M-36.3%
Enterprise value$592.29M

Returns & leverage

See full
Debt / equity0.5×
Current ratio11.8×

Where this comes from

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Eikon Therapeutics, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216791
Line itemMarch 31,2026December 31,2025
Redeemable convertible preferred stock, $0.0001 par value; no shares authorized, issued and outstanding as of March 31, 2026 and 262,597,889 shares authorized, 222,658,133 shares issued and outstanding, and aggregate liquidation preference of $1,159,762 as of December 31, 20251,161,470
Stockholders’ equity (deficit):
Preferred stock, $0.0001 par value; 50,000,000 shares authorized and no shares issued and outstanding as of March 31, 2026 and no shares authorized, issued and outstanding as of December 31, 2025
Common stock, $0.0001 par value; 500,000,000 shares authorized and 54,138,555 shares issued and outstanding as of March 31, 2026 and 340,650,000 shares authorized and 3,068,490 shares issued and outstanding as of December 31, 20255
Additional paid-in capital1,554,13341,475
Accumulated deficit(1,003,467)(920,509)
Total stockholders’ equity (deficit)550,671(879,034)
Total liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit)$850,826$594,734

Item 1. Condensed Financial Statements (Unaudited).

FAQ

What is Eikon Therapeutics, Inc.'s total liabilities & equity?
Eikon Therapeutics, Inc. (EIKN) reported total liabilities & equity of $850.83M in Q1 2026.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Eikon Therapeutics, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude